NASDAQ · LGND
Ligand Pharmaceuticals Incorporated
$317.33-$1.45 (-0.45%)
Ligand Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
Loading market information…
OTC · TSTS · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
That Marketing Solution, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow That Marketing Solution, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
That Marketing Solution, Inc., a development stage company, focuses on the development, manufacturing, advertising, sale, and marketing of nutritional products. It acquired the rights to a proprietary formula for a blend of nutritional supplements called Low-T capsules that are intended to be a natural, non-FDA regulated, and over-the-counter supplement, which addresses the primary contributing factors of decreased levels of testosterone in males over the age of 30. The company was formerly known as Vista Holding Group, Corp. and changed its name to That Marketing Solution, Inc. in September 2014. That Marketing Solution, Inc. was founded in 2012 and is based in Salt Lake City, Utah.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$317.33-$1.45 (-0.45%)
Ligand Pharmaceuticals Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.85% below the high.
$7.02+$0.28 (+4.08%)
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
$1.28$0.00 (0.0%)
Sonendo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.63% below the high.
$0.02$0.00 (0.0%)
Easy Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
IR Biosciences Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Adastra Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.0% below the high.
$0.00$0.00 (0.0%)
ScripsAmerica, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Todos Medical Ltd.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
